Is rituximab an effective treatment of refractory calcinosis?

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Dubos, Maria ^a   Ly, Kim ^a   Martel, Clothilde ^a   Fauchais, Anne Laure ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; RITUXIMAB; SODIUM THIOSULFATE; THALIDOMIDE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CALCINOSIS; CASE REPORT; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY; FEMALE; HUMAN; MALE; MIDDLE AGED; MYOSITIS; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLEROMYOSITIS; TUMOR CALCINOSIS; COMPLICATION; DERMATOMYOSITIS; MIXED CONNECTIVE TISSUE DISEASE; SYSTEMIC SCLEROSIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CALCINOSIS; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; RITUXIMAB; SCLERODERMA, SYSTEMIC;

EID: 84974717516     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2015-213179     Document Type: Article

References (13)

1. Battistella M, Cribier B. Les calcinoses cutanées. Rev Rhum Monogr 2011;78:178-86.
2. Reiter N, El-Shabrawi L, Leinweber B, et al. Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 2011;65:1-12, quiz 13-4.
3. Boulman N, Slobodin G, Rozenbaum M, et al. Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805-12.
4. Reiter N, El-Shabrawi L, Leinweber B, et al. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 2011;65:15-22.
5. Bienvenu B. [Treatment of subcutaneous calcinosis in systemic disorders]. Rev Med Interne 2014;35:444-52.
6. Daoussis D, Antonopoulos I, Liossis SN, et al. Treatment of systemic sclerosis-Associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9.
7. De Paula DR, Klem FB, Lorencetti PG, et al. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013;32:281-3.
8. Hurabielle C, Allanore Y, Kahan A, et al. Flare of calcinosis despite rituximab therapy. Semin Arthritis Rheum 2014;44:e5-6.
9. Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 2015;14:1072-8.
10. Allanore Y, Cabane J, Mouthon L, Groupe Français de Recherche sur la Sclérodermie. Sclérodermies. 2éme édition. Paris: Med-Line éd, 2011.
11. Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011;38:1436-40.
12. Narváez J, Sancho JJA, Castellvi I, et al. Long-term efficacy of rituximab in systemic sclerosis. Arthritis Rheum 2014;66(Suppl 10):S1-1402.
13. Girard C, Vincent T, Bessis D. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case]. Ann Dermatol Venereol 2013;140:628-34.